# Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

> **NCT00595985** · PHASE2 · TERMINATED · sponsor: **Fudan University** · enrollment: 5 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** sorafenib

## Key facts

- **NCT ID:** NCT00595985
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** low response rate, no evidence of PFS or OS improved.
- **Last updated:** 2009-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00595985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00595985, "Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00595985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*